AEON AEON Biopharma, Inc.
Listings ·
AEON Biopharma asked stockholders to approve a reverse stock split of between 1-for-2 and 1-for-100, to be voted on December 15, 2026. The stock last sold at $0.24 on October 23, and NYSE American's cumulative ratio limit counts the company's 1-for-72 split of February 2025.
AEON Biopharma received official minutes from a Type 2b meeting with the FDA on its BOTOX biosimilar. It plans to file an IND for a comparative pharmacodynamic study in the fourth quarter of 2026.
AEON Biopharma reported $3.4 million in cash at June 30, 2026, and said upfront proceeds from its July offering extend its runway into the first quarter of 2027. The company also regained NYSE American compliance on August 3, 2026.
NYSE Regulation confirmed that AEON resolved the stockholders' equity deficiencies it had reported, after an offering that closed on July 15, 2026. The company expects the below-compliance indicator to be removed from its trading symbol.
The underwriters bought 4,696,102 additional shares on July 23, 2026, for about $1.5 million in gross proceeds. Lake Street Capital Markets, LLC acted as representative of the underwriters.
The offering was priced at $0.3221 per share and accompanying warrants. Lake Street Capital Markets, LLC is sole bookrunner, and Laidlaw & Company (UK) Ltd. is lead manager.
The notice cites a stockholders' deficit of approximately $55 million as of December 31, 2025. AEON keeps its listing and has until August 3, 2026 to regain compliance.
AEON Biopharma exchanged its senior secured convertible notes held by Daewoong for new shares, pre-funded warrants and a smaller $1,500,000 note after stockholders approved the deal on January 21, 2026. The swap adds dilution, and the second closing of its private placement is still pending.
NYSE American accepted AEON Biopharma's plan to regain compliance with three continued listing standards and gave the company until August 3, 2026. The 8-K does not say which financial measures the company missed, and the company's migraine trials failed their primary endpoints.
AEON Biopharma priced 40,000,000 units at $0.50 each for about $20.0 million gross, with Aegis Capital Corp. as sole book-running manager. Each unit carries two warrants that cannot be exercised until stockholders approve them, and their exercise price can reset lower.
AEON Biopharma, Inc. is a biopharmaceutical company developing ABP-450, a botulinum toxin complex, as a biosimilar to Botox (onabotulinumtoxinA) for therapeutic indications. The company plans to pursue United States approval through a biologics license application under Section 351(k) of the Public Health Service Act. It holds exclusive development and commercialization rights for ABP-450 in therapeutic indications across the United States, Canada, the European Union, the United Kingdom and certain other territories. ABP-450 is manufactured by Daewoong Pharmaceutical Co., Ltd. and is approved as a biosimilar in Mexico, India and Philippines. In the United States, the same toxin is approved for aesthetic use under the brand name Jeuveau, marketed by Evolus, Inc. The company met with the FDA in January 2026 to discuss its analytical similarity strategy and plans to complete most of its analytical comparability program in 2026. The company estimates the therapeutic botulinum toxin market at least $3.3 billion in 2025.
| Product or program | What it is | Stage |
|---|---|---|
| ABP-450 | Botulinum toxin complex as a biosimilar to Botox for therapeutic indications | Analytical similarity program ongoing under the 351(k) pathway |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $4.1 million | $14.2 million |
| Net income (loss) | -$39.2 million | $42.0 million |
| Cash from operations | -$17.3 million | -$20.3 million |
| Cash and equivalents | $3.0 million | $13,000 |
Our latest story on this, dated Oct 26, 2026: "AEON Biopharma seeks approval for a reverse split of up to 1-for-100". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 12, 2026: "AEON reports second-quarter 2026 results and a $15.3 million financing". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 21, 2026: "AEON Biopharma completes Daewoong note exchange, issuing 11,918,380 shares and a $1,500,000 note". The story links the filing or release it is based on. Read the story.
AEON Biopharma, Inc. trades under the ticker AEON on AMEX.
AEON Biopharma, Inc. is listed on AMEX.
The SEC Central Index Key (CIK) for AEON Biopharma, Inc. is 1837607. Its filings are on SEC EDGAR.
49,882,790 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-12.
Our directory records AEON Biopharma, Inc. under United States.
Our directory classifies AEON Biopharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for AEON Biopharma, Inc. is US00791X2099.
aibio.space lists AEON Biopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
AEON Biopharma, Inc. is a biopharmaceutical company developing ABP-450, a botulinum toxin complex, as a biosimilar to Botox (onabotulinumtoxinA) for therapeutic indications. The company plans to pursue United States approval through a biologics license application under Section 351(k) of the Public Health Service Act.
ABP-450: Botulinum toxin complex as a biosimilar to Botox for therapeutic indications Stage: Analytical similarity program ongoing under the 351(k) pathway.
AEON Biopharma, Inc. reported a net loss of $39.2 million for the fiscal year ended Dec 31, 2025, and used $17.3 million of cash in operations, per its annual report to the SEC.
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a financing. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.02,5.07,7.01,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,5.07,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 424B5. Source
Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio